|
1.
|
|
22 p, 4.7 MB |
Loss of microRNA-135b Enhances Bone Metastasis in Prostate Cancer and Predicts Aggressiveness in Human Prostate Samples
/
Olivan, M (Hospital Universitari Vall d'Hebron) ;
García, Marta (Institut de Recerca Sant Joan de Déu) ;
Suárez, Leticia (Hospital Universitari Vall d'Hebron) ;
Guiu, Marc (Institut de Recerca Biomèdica) ;
Gros, Laura (Hospital Universitari Vall d'Hebron) ;
Méndez Fernández, Olga (Hospital Universitari Vall d'Hebron) ;
Rigau, Marina (Hospital Universitari de Bellvitge) ;
Reventós, Jaume (Hospital Universitari de Bellvitge) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron) ;
de Torres, Inés (Hospital Universitari Vall d'Hebron) ;
Planas, Jacques (Hospital Universitari Vall d'Hebron) ;
de la Cruz, Xavier (Hospital Universitari Vall d'Hebron) ;
Gomis, Roger R. (Hospital Universitari de Bellvitge) ;
Morote Robles, Juan (Hospital Universitari Vall d'Hebron) ;
Rodríguez-Barrueco, Ruth (Hospital Universitari de Bellvitge) ;
Santamaría, Anna (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Prostate cancer (PCa) is the most prevalent cancer in males worldwide, and it was the fifth leading cause of cancer mortality in this group in 2020. Near 70% of advanced-stage PCa patients will undergo bone metastasis, suffering pathological complications that severely affect patients' quality of life and probably progress in most cases to lethal PCa. [...]
2021 -  10.3390/cancers13246202
Cancers, Vol. 13 (december 2021)
|
|
|
2.
|
|
18 p, 1.4 MB |
Dickkopf Proteins and Their Role in Cancer : A Family of Wnt Antagonists with a Dual Role
/
Giralt, Irina (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gallo-Oller, Gabriel (Vall d'Hebron Institut d'Oncologia) ;
Navarro Barea, Natalia (Vall d'Hebron Institut d'Oncologia) ;
Zarzosa, Patricia (Vall d'Hebron Institut d'Oncologia) ;
Pons, Guillem (Vall d'Hebron Institut d'Oncologia) ;
Magdaleno, Ainara (Vall d'Hebron Institut d'Oncologia) ;
Segura, Miguel F. (Vall d'Hebron Institut d'Oncologia) ;
Sánchez de Toledo, José (Vall d'Hebron Institut d'Oncologia) ;
Moreno, Lucas (Hospital Universitari Vall d'Hebron) ;
Gallego, Soledad (Hospital Universitari Vall d'Hebron) ;
Roma, Josep (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
The Wnt signaling pathway regulates crucial aspects such as cell fate determination, cell polarity and organogenesis during embryonic development. Wnt pathway deregulation is a hallmark of several cancers such as lung, gastric and liver cancer, and has been reported to be altered in others. [...]
2021 - 10.3390/ph14080810
Pharmaceuticals, Vol. 14 (august 2021)
|
|
|
3.
|
|
|
4.
|
|
14 p, 2.6 MB |
Analysis of Cancer Genomic Amplifications Identifies Druggable Collateral Dependencies within the Amplicon
/
Pons, Guillem (Hospital Universitari Vall d'Hebron) ;
Gallo-Oller, Gabriel (Hospital Universitari Vall d'Hebron) ;
Navarro Barea, Natalia (Hospital Universitari Vall d'Hebron) ;
Zarzosa, Patricia (Hospital Universitari Vall d'Hebron) ;
Sansa-Girona, Júlia (Hospital Universitari Vall d'Hebron) ;
García-Gilabert, Lia (Hospital Universitari Vall d'Hebron) ;
Magdaleno, Ainara (Hospital Universitari Vall d'Hebron) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron) ;
Sánchez de Toledo Codin, Josep (Hospital Universitari Vall d'Hebron) ;
Gallego, Soledad (Hospital Universitari Vall d'Hebron) ;
Moreno, Lucas (Hospital Universitari Vall d'Hebron) ;
Roma, Josep (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
The identification of novel therapeutic targets for specific cancer molecular subtypes is crucial for the development of precision oncology. In the last few years, CRISPR/Cas9 screens have accelerated the discovery and validation of new targets associated with different tumor types, mutations, and fusions. [...]
2023 - 10.3390/cancers15061636
Cancers, Vol. 15 (march 2023)
|
|
|
5.
|
|
17 p, 1.1 MB |
Targeting the Hedgehog Pathway in Rhabdomyosarcoma
/
Zarzosa, Patricia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
García-Gilabert, Lia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Hladun, Raquel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Guillén, Gabriela (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gallo-Oller, Gabriel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Pons, Guillem (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Sansa-Girona, Julia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Sánchez de Toledo Codin, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Moreno, Lucas (Vall d'Hebron Institut d'Oncologia) ;
Gallego, Soledad (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca)
In the first sections of this review, we provide a comprehensive description of the Hedgehog signalling pathway in mammals and the main general models of pathway activation. Subsequently, the review focuses on the oncogenic role played by this pathway in rhabdomyosarcoma and the inhibitors developed to date, as well as the clinical trials available in sarcomas. [...]
2023 - 10.3390/cancers15030727
Cancers, Vol. 15 (january 2023)
|
|
|
6.
|
|
9 p, 2.3 MB |
The Novel KIF1A Missense Variant (R169T) Strongly Reduces Microtubule Stimulated ATPase Activity and Is Associated With NESCAV Syndrome
/
Aguilera, Cinthia (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Hümmer, Stefan (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Masanas, Marc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Gabau, Elisabeth (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Guitart, Míriam (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Jeyaprakash, A. Arockia (University of Edinburgh) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Santamaría, Anna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Ruiz, Anna (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
KIF1A is a microtubule-dependent motor protein responsible for fast anterograde transport of synaptic vesicle precursors in neurons. Pathogenic variants in KIF1A have been associated with a wide spectrum of neurological disorders. [...]
2021 - 10.3389/fnins.2021.618098
Frontiers in Neuroscience, Vol. 15 (may 2021)
|
|
|
7.
|
|
20 p, 6.0 MB |
Multi-Smart and Scalable Bioligands-Free Nanomedical Platform for Intratumorally Targeted Tambjamine Delivery, a Difficult to Administrate Highly Cytotoxic Drug
/
Pérez-Hernández, Marta (Institut d'Investigació Biomèdica de Bellvitge) ;
Cuscó, Cristina (Nanobiotechnological Polymers Division) ;
Benítez-García, Cristina (Institut d'Investigació Biomèdica de Bellvitge) ;
Bonelli, Joaquin (Nanobiotechnological Polymers DivisionBusiness Park) ;
Nuevo-Fonoll, Marina (Universitat de Barcelona. Departament de Patologia i Terapèutica Experimental) ;
Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martínez-García, David (Institut d'Investigació Biomèdica de Bellvitge) ;
Arias-Betancur, Alain (Universidad de La Frontera) ;
García-Valverde, María (Universidad de Burgos) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Quesada, Roberto (Universidad de Burgos) ;
Rocas, Josep (Nanobiotechnological Polymers Division) ;
Soto-Cerrato, Vanessa (Institut d'Investigació Biomèdica de Bellvitge) ;
Pérez-Tomás, Ricardo (Universitat de Barcelona) ;
Universitat Autònoma de Barcelona
Cancer is one of the leading causes of mortality worldwide due, in part, to limited success of some current therapeutic approaches. The clinical potential of many promising drugs is restricted by their systemic toxicity and lack of selectivity towards cancer cells, leading to insufficient drug concentration at the tumor site. [...]
2021 - 10.3390/biomedicines9050508
Biomedicines, Vol. 9 (may 2021)
|
|
|
8.
|
|
|
9.
|
|
10 p, 1.7 MB |
The antitumour drug ABTL0812 impairs neuroblastoma growth through endoplasmic reticulum stress-mediated autophagy and apoptosis
/
París-Coderch, Laia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Jiménez Jiménez, Carlos (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Erazo, Tatiana (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Muñoz-Guardiola, Pau (Ability Pharmaceuticals) ;
Masanas, Marc (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Antonelli, Roberta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Boloix, Ariadna (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Alfón, José (Ability Pharmaceuticals) ;
Pérez-Montoyo, Héctor (Ability Pharmaceuticals) ;
Yeste-Velasco, Marc (Ability Pharmaceuticals) ;
Domènech, Carles (Ability Pharmaceuticals) ;
Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Sánchez de Toledo Codin, Josep (Vall d'Hebron Institut d'Oncologia) ;
Moreno, Lucas (Vall d'Hebron Institut d'Oncologia) ;
Lizcano de Vega, José Miguel (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Gallego, Soledad (Vall d'Hebron Institut d'Oncologia) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Neuroblastoma is the leading cause of cancer death in children aged 1 to 4 years. Particularly, five-year overall survival for high-risk neuroblastoma is below 50% with no curative options when refractory or relapsed. [...]
2020 - 10.1038/s41419-020-02986-w
Cell death and disease, Vol. 11 (september 2020)
|
|
|
10.
|
|
17 p, 3.9 MB |
CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models
/
Antonelli, Roberta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Jiménez Jiménez, Carlos (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Riley, Misha (Massachusetts General Hospital (Boston)) ;
Servidei, Tiziana (Fondazione Policlinico Universitario "A. Gemelli" (Roma, Itàlia)) ;
Riccardi, Riccardo (Fondazione Policlinico Universitario "A. Gemelli" (Roma, Itàlia)) ;
Soriano, Aroa (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Roma, Josep (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martinez-Saez, Elena (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Martini, Maurizio (Catholic University of Sacred Heart) ;
Ruggiero, Antonio (Fondazione Policlinico Universitario "A. Gemelli" (Roma, Itàlia)) ;
Moreno, Lucas (Vall d'Hebron Institut d'Oncologia) ;
Sánchez de Toledo Codin, Josep (Vall d'Hebron Institut d'Oncologia) ;
Gallego, Soledad (Vall d'Hebron Institut d'Oncologia) ;
Bové, Jordi (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Hooker, Jacob M. (Massachusetts General Hospital (Boston)) ;
Segura, Miguel F. (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona
Pediatric ependymoma (EPN) is a highly aggressive tumor of the central nervous system that remains incurable in 40% of cases. In children, the majority of cases develop in the posterior fossa and can be classified into two distinct molecular entities: EPN posterior fossa A (PF-EPN-A) and EPN posterior fossa B (PF-EPN-B). [...]
2020 - 10.3390/cancers12071922
Cancers, Vol. 12 (july 2020)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
